Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the maximum tolerated dose of ribavirin, when given
in combination with low-dose ara-C and to determine if it is safe and well-tolerated in
patients with acute myeloid leukemia.